Topical Itraconazole in Treating Patients With Basal Cell Cancer

Trial ID or NCT#

NCT02735356

Status

not recruiting iconNOT RECRUITING

Purpose

This phase 0 trial studies how well itraconazole gel works in treating patients with basal cell cancer. Itraconazole gel may help to treat basal cell tumors in patients.

Official Title

A Case Study of the Effects of Topical Itraconazole on Pharmacodynamic Modulation of Hedgehog Target Gene Expression in Basal Cell Carcinomas in Patients

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - The subject must sign and date all informed consent statements; children will sign the assent form and their guardian will sign the consent form - The subject must be willing to apply the medications twice daily for 1 month - The subjects must have at least four BCCs in non-cosmetically sensitive sites - For women of child-bearing potential, a negative urine pregnancy test - Women of child-bearing potential are expected to use an effective method of birth control to prevent exposing a fetus to potentially dangerous agent with unknown risk - For male patients with female partners of childbearing potential, agreement to use adequate contraception while you are participating in the study and 1 month after applying your last dose
Exclusion Criteria:
  1. - Pregnancy or breast-feeding - History of congestive heart failure or other findings of ventricular dysfunction - History of current evidence of malabsorption or liver disease - Current immunosuppression or taking immunosuppressive drugs - Taking oral itraconazole - Taking any medication known to affect hedgehog (HH) signaling pathway - The subject has used topical or systemic therapies that might interfere with the evaluation of the study medication during the study; specifically these include the topical use to the study tumors of: glucocorticoids (ii) retinoids (e.g., etretinate, isotretinoin, tazarotene, tretinoin, adapalene) systemically or topically (iii) alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to more than 5% of the skin during the six months prior to study entry (iv) 5-fluorouracil or imiquimod; also - treatment with systemic chemotherapy or agents known to be inhibitors of HH signaling within 60 days to starting study medication
View All Criteria
Show Less

Investigator(s)

Anthony Oro, MD, PhD
Anthony Oro, MD, PhD
Hair loss specialist, Dermatologic oncologist, Cutaneous oncology specialist, Skin stem cell specialist
Eugene and Gloria Bauer Professor

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov